Lead sponsor

GlaxoSmithKline

29 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials led

Ongoing

8,769

Total enrollment

673

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1

Phase 2

Phase 3

Not applicable

Trials by status

Recruiting

Active, not recruiting

Completed

Terminated

Withdrawn

Trials led

REFLECT-2mild-to-moderate ADN/ACompleted1,496

REFLECT-3mild-to-moderate ADPh 3Completed1,468

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate AlzheimersAge 51-91Ph 3Terminated1,461

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 3Completed862

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed682

Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Diseasemild-to-moderate ADPh 2Completed576

A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Diseasemild-to-moderate ADPh 2Completed380

PROGRESS-ADMCI due to AD / mild AD dementiaPh 2Active, not recruiting367

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate AlzheimersStudy partner/caregiver requiredPh 3Terminated331

Open-label Extension Study in Participants With Early Alzheimer's DiseaseAge 50-85Ph 2Recruiting220

SB-742457 And Donepezil In Alzheimer's Diseasemild-to-moderate ADPh 2Completed200

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's DiseaseAlzheimer's diseasePh 2Completed196

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's DiseaseAlzheimer's diseasePh 2Completed124

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's DiseaseMMSE 16-26Ph 2Completed80

Rosi XRHealthy volunteersPh 1Completed60

A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.Age 18-55Ph 1Completed50

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 1Completed50

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's DiseaseStudy partner/caregiver requiredPh 2Completed33

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed28

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy VolunteersAge 18-55Ph 1Completed27

Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease PatientMMSE 20-26Ph 1Completed19

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)Alzheimer's diseasePh 1Completed14

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers DiseaseMMSE 16-26Ph 2Terminated12

GSK2647544 RD, DDI in Healthy Young and Elderly VolunteersAge ≥18Ph 1Terminated12

A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.Age 60-85Ph 1Completed12

An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.Age 35-49Ph 1Completed5

A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.Age 30-55Ph 1Terminated4

Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy VolunteersAge 18-65Ph 1Withdrawnnot disclosed

Rosi XRAge 18-45Ph 1Withdrawnnot disclosed